BIOLINERX Ltd/S (BLRX) Stock Price Down 14.5%

Share on StockTwits

BIOLINERX Ltd/S (NASDAQ:BLRX) shares fell 14.5% during mid-day trading on Thursday . The company traded as low as $1.11 and last traded at $1.24. 5,044,791 shares changed hands during trading, an increase of 716% from the average session volume of 618,452 shares. The stock had previously closed at $1.45.

A number of brokerages have issued reports on BLRX. ValuEngine upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 4th. Zacks Investment Research lowered shares of BIOLINERX Ltd/S from a “buy” rating to a “hold” rating in a research report on Monday. HC Wainwright set a $4.00 target price on shares of BIOLINERX Ltd/S and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Maxim Group restated a “buy” rating and set a $2.00 target price on shares of BIOLINERX Ltd/S in a research report on Monday, August 13th. Finally, MED began coverage on shares of BIOLINERX Ltd/S in a research report on Wednesday, August 1st. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $2.50.

The stock has a market capitalization of $113.94 million, a PE ratio of -5.26 and a beta of 0.49.

BIOLINERX Ltd/S (NASDAQ:BLRX) last announced its earnings results on Monday, August 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. Equities research analysts expect that BIOLINERX Ltd/S will post -0.22 earnings per share for the current year.

About BIOLINERX Ltd/S (NASDAQ:BLRX)

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Further Reading: Buyback

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply